BioSpace News Archive

Female Project Manager running work on project timeline. Progress in business, Work process or work process, Timeline to success, Roadmap, Vector design illustration.

Obesity

Obesity Space Abuzz With Oral, Amylin Assets as Momentum Rides Into 2026

Biopharma’s obsession with the weight loss sector—projected to exceed $130 billion in revenue by 2035—shows no signs of slowing down as analysts gear up for a year that will test the oral market and provide key data on novel mechanisms.

February 6, 2026

·

4 min read

·

Mark Zipkin

Illustration of cardboard box filled with office supplies, a computer keyboard, lamp, and a potted plant

Layoff Tracker

Charles River, Thermo Fisher Lay Off Staff Amid Site Closures

Follow along as BioSpace tracks job cuts and restructuring initiatives.

February 6, 2026

·

51 min read

·

BioSpace Editorial Staff

FDA Commissioner Dr. Marty Makary delivers remarks after President Donald Trump made an announcement on drug pricing, Tuesday, September 30, 2025, in the Oval Office. (Official White House Photo by Joyce N. Boghosian)

GLP-1

Makary Blasts ‘Illegal Copycat Drugs’ as Hims Launches Compounded Wegovy Pill

Novo Nordisk has also spoken out strongly against Hims & Hers’ compounded Wegovy pill, with CEO Maziar Mike Doustdar telling investors the knockoff version is a waste of money.

February 6, 2026

·

1 min read

·

Tristan Manalac

IPO Initial Public Offering finance business concept. 3D render vector illustration of Trading on IPO Initial Public Offering, Business Startup and Stock Market Concept. Public offering share launch

IPO

Eikon Clocks Largest IPO Since 2024, Generate, AgomAb Follow

Analysts are cautiously optimistic about an IPO rebound for biopharma. BioSpace is keeping track of companies that seek to trade on the public markets this year.

February 6, 2026

·

5 min read

·

Tristan Manalac

A contemporary artistic collage featuring a hand holding a trophy. The concept of victory and achievement.

Immunology and inflammation

Priovant Plots Path to Phase 3 as Brepocitinib Clears Mid-Stage Skin Disease Study

According to Priovant, the Phase 2 BEACON study is the first industry-sponsored placebo-controlled trial in cutaneous sarcoidosis to deliver positive data.

February 6, 2026

·

2 min read

·

Tristan Manalac

Psychedelics

AbbVie CSO Touts ‘Breakthrough Type Therapy’ Psychedelic as J&J’s Spravato Keeps Growing

Sales of Johnson & Johnson’s esketamine-based nasal spray jumped in the fourth quarter last year, priming the pump for a suite of other pharmas, including AbbVie, champing at the bit with their own psychedelics.

February 6, 2026

·

2 min read

·

Dan Samorodnitsky

Business meeting idea and planning with strategy as a corporate concept with a mechanical wheel bridge as diverse multiracial businesspeople joining together as a symbol for people diversity and success with 3D render elements.

Earnings

Biogen’s ‘Bridge To Growth’ Cuts Through a Stacked Phase 3 Pipeline

With Biogen’s multiple sclerosis portfolio facing more generic pressure than ever, the company is eyeing a busy late-stage pipeline and hunting for deals to build its return to growth.

February 6, 2026

·

2 min read

·

Annalee Armstrong

Press Releases

Anaptys Announces Participation at Upcoming Investor Conferences

February 6, 2026

·

2 min read

Press Releases

CooperCompanies Announces Release Date for First Quarter 2026